HKG: 9969

InnoCare Pharma Secures NMPA Clinical Trial Approval for ICP‑B381 – First Bispecific PSMA/STEAP1 ADC From Its Proprietary Platform, Targeting Prostate Cancer and Other Solid Tumors

InnoCare Pharma Limited (HKG: 9969; SHA: 688428) announced that China’s National Medical Products Administration (NMPA)...

Company PIC

InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth

Fineline Cube Aug 25, 2026

InnoCare Pharma Limited (HKG: 9969; SHA: 688428) reported interim results for the first half of...

Company Drug

InnoCare Pharma’s Orelabrutinib-Mesutoclax Combination Receives Breakthrough Therapy Designation for Marginal Zone Lymphoma

Fineline Cube Aug 5, 2026

InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced that the combination regimen of orelabrutinib and...

Company Drug

InnoCare’s TYK2 Inhibitor Fadeucravacitinib Hits Primary Endpoint in Phase III Psoriasis Trial

Fineline Cube Jul 28, 2026

InnoCare Pharma (HKG: 9969) announced that the pivotal Phase III clinical trial of its potent,...

Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Fineline Cube Jul 16, 2026

InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced today that the Phase III registrational clinical...

Company Drug

InnoCare Pharma’s BTK Inhibitor Orelabrutinib Gains NMPA Review Acceptance for Primary Immune Thrombocytopenia Indication

Fineline Cube May 29, 2026

InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced that the Center for Drug Evaluation (CDE)...

Company Drug

InnoCare Pharma Secures Australian TGA Approval for Hibruka in Relapsed/Refractory Mantle Cell Lymphoma – Highly Selective BTK Inhibitor Expands International Footprint

Fineline Cube May 28, 2026

InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced that Australia’s Therapeutic Goods Administration (TGA) has...

Company Drug

InnoCare Pharma Doses First Patient in ICP-054 (ZB021) Trial – Novel Oral IL-17AA/AF Inhibitor Shows Promise for Autoimmune Diseases

Fineline Cube May 14, 2026

InnoCare Pharma (HKG: 9969) announced the dosing of the first subject in a clinical study...

Company

InnoCare Pharma Reports 2025 Profitability – Revenue Surges 135% to RMB 2.37B on Global BD Success

Fineline Cube Mar 26, 2026

InnoCare Pharma (HKG: 9969, SHA: 688428) announced 2025 financial results, achieving first-ever annual profitability with...

Company Drug

InnoCare’s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors – Next‑Gen TRK Inhibitor Expands Label

Fineline Cube Mar 2, 2026

InnoCare Pharma Limited (SHA: 688428, HKG: 9969) announced that the Center for Drug Evaluation (CDE) of China’s...

Company Drug

InnoCare’s Soficitinib Wins NMPA Approval for Phase 2/3 TYK2 Urticaria Study

Fineline Cube Dec 18, 2025

InnoCare Pharma Limited (SHA: 688428, HKG: 9969) announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared

Fineline Cube Dec 16, 2025

InnoCare Pharma Limited (SHA: 688428, HKG: 9969) announced that its self‑developed novel BTK inhibitor orelabrutinib...

Company Drug

InnoCare’s Zurletrectinib Wins NMPA Nod as China’s First Next-Gen TRK Inhibitor

Fineline Cube Dec 13, 2025

InnoCare Pharma Limited (SHA: 688428, HKG: 9969) announced that its self‑developed next‑generation TRK inhibitor, Zurletrectinib...

Company Drug

InnoCare Announces First Patient Dosing of ICP‑B794, a Novel B7‑H3 Targeting ADC

Fineline Cube Oct 30, 2025

China‑based InnoCare Pharma Limited (SHA: 688428, HKG: 9969) today disclosed that its self‑developed antibody‑drug conjugate...

Company Deals Drug

InnoCare, Zenas, Orelabrutinib: $2 B Licensing Deal Fuels MS Therapeutic Pipeline

Fineline Cube Oct 9, 2025

InnoCare Pharma Limited (HKG: 9969) announced a landmark exclusive license and subscription agreement with Zenas...

Company Drug

InnoCare Pharma Secures Singapore HSA Approval for Orelabrutinib in Relapsed MZL

Fineline Cube Sep 8, 2025

Shanghai‑based InnoCare Pharma (HKG: 9969, SHA: 688428) announced on September 8, 2025 that its Bruton’s tyrosine kinase...

Company Drug Policy / Regulatory

InnoCare Pharma’s ICP-723 Joins China’s SPARK Project for Pediatric Solid Tumors

Fineline Cube Aug 22, 2025

China’s Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has announced...

Company

InnoCare Pharma’s Orelabrutinib Powers 74.3% Revenue Surge in 2025 H1

Fineline Cube Aug 20, 2025

Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) has unveiled its 2025 interim results, showcasing a...

Company Drug

InnoCare Pharma Receives FDA Approval for Mesutoclax in Myeloid Malignancies

Fineline Cube Jul 14, 2025

Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical trial...

Company Drug

InnoCare Pharma Receives NMPA Clinical Approval for Innovative ADC B7-H3

Fineline Cube Jul 3, 2025

Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical approval...

HKG: 9969

InnoCare Pharma Secures NMPA Clinical Trial Approval for ICP‑B381 – First Bispecific PSMA/STEAP1 ADC From Its Proprietary Platform, Targeting Prostate Cancer and Other Solid Tumors

InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth

InnoCare Pharma’s Orelabrutinib-Mesutoclax Combination Receives Breakthrough Therapy Designation for Marginal Zone Lymphoma

InnoCare’s TYK2 Inhibitor Fadeucravacitinib Hits Primary Endpoint in Phase III Psoriasis Trial

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

InnoCare Pharma’s BTK Inhibitor Orelabrutinib Gains NMPA Review Acceptance for Primary Immune Thrombocytopenia Indication

InnoCare Pharma Secures Australian TGA Approval for Hibruka in Relapsed/Refractory Mantle Cell Lymphoma – Highly Selective BTK Inhibitor Expands International Footprint

InnoCare Pharma Doses First Patient in ICP-054 (ZB021) Trial – Novel Oral IL-17AA/AF Inhibitor Shows Promise for Autoimmune Diseases

InnoCare Pharma Reports 2025 Profitability – Revenue Surges 135% to RMB 2.37B on Global BD Success

InnoCare’s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors – Next‑Gen TRK Inhibitor Expands Label

InnoCare’s Soficitinib Wins NMPA Approval for Phase 2/3 TYK2 Urticaria Study

Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared

InnoCare’s Zurletrectinib Wins NMPA Nod as China’s First Next-Gen TRK Inhibitor

InnoCare Announces First Patient Dosing of ICP‑B794, a Novel B7‑H3 Targeting ADC

InnoCare, Zenas, Orelabrutinib: $2 B Licensing Deal Fuels MS Therapeutic Pipeline

InnoCare Pharma Secures Singapore HSA Approval for Orelabrutinib in Relapsed MZL

InnoCare Pharma’s ICP-723 Joins China’s SPARK Project for Pediatric Solid Tumors

InnoCare Pharma’s Orelabrutinib Powers 74.3% Revenue Surge in 2025 H1

InnoCare Pharma Receives FDA Approval for Mesutoclax in Myeloid Malignancies

InnoCare Pharma Receives NMPA Clinical Approval for Innovative ADC B7-H3

You Missed

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories